Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-end report 2020: Higher deliveries and better capacity utilization improved earnings in Q4

The fourth quarter · Revenue was SEK 16,988 (16,973) million · EBITDA was SEK 1,439 (-127) million · Operating profit/loss was SEK 557 (-1,131) million · Earnings per share were SEK 0.33 (-1.21) · The Board proposes that no dividend will be paid for 2020Comments by the CEO The year 2020 was affected by a weak market as a consequence of Covid-19, and SSAB’s operating result fell to SEK -325 (2,159) million. The market picked up during the autumn and SSAB’s shipments and capacity utilization improved. This lifted earnings for the fourth quarter of 2020 to SEK 557 (-1,131)

Stora Enso will close its Virdia operations in the United States

STORA ENSO OYJ INVESTOR NEWS 29 January 2021 at 8:29 EETStora Enso has decided to permanently close its US-based Virdia operations during 2021. Virdia was acquired in 2014 and has focused on conversion of cellulosic biomass from sugar cane bagasse into refined sugars. The operations have consisted of a research centre in Danville, Virginia and a demo plant in Raceland, Louisiana, which will both be closed. The closure is in line with Stora Enso’s strategic choices in R&D to drive future growth and value creation from forest-based materials. Furthermore, today, the company’s innovation

Proposals by the Board of Directors to the Stora Enso Oyj Annual General Meeting 2021

STORA ENSO OYJ STOCK EXCHANGE RELEASE 29 January 2021 at 8:29 EETProposals by the Board of Directors to the Annual General Meeting 2021 The Board of Directors of Stora Enso Oyj (the "Company") has decided that the Annual General Meeting (the "AGM") will be held on Friday 19 March 2021 at 4 p.m. Finnish time with exceptional meeting procedures based on the temporary legislative act to limit the spread of the Covid-19 pandemic (677/2020). The AGM will be held without the presence of shareholders or their representatives in order to hold the meeting in a predictable manner, taking into

SSAB concludes IJmuiden discussions with Tata Steel

During the fourth quarter of 2020, SSAB announced that it was in discussions with Tata Steel concerning a possible acquisition of the IJmuiden steel mill and related downstream assets. After deeper analysis and discussions, it became clear that there were limited possibilities to integrate IJmuiden into the SSAB strategic framework. Discussions with Tata Steel have therefore concluded.“We have carefully evaluated Tata Steel IJmuiden and have concluded that an acquisition would be difficult for technical reasons. We cannot be sufficiently certain that we could implement our industrial plan

Invitation: Presentation of Ambea’s year-end 2020 results

Hosts: Benno Eliasson, acting CEO and CFO, and Jacob Persson, Head of Group Business Control and Investor Relations.On February 16th at 07:00 (CET) Ambea will publish its’ year-end 2020 results. In connection to the announcement, Ambea will host a telephone conference at 10:00 (CET) on Tuesday, February 16th. The presentation will be held in English and also available as webcast on www.ambea.com or direct link: https://edge.media-server.com/mmc/p/8z98xf9z To ensure that you are connected to the conference call, please dial in at least ten minutes before the start of the conference

Change in number of shares and votes in Camurus

Lund, Sweden — 29 January 2021 — During January 2021, 1,300 subscription warrants in Camurus’ subscription warrant series 2017/2020 have been exercised and as a consequence the number of shares and votes has increased by 1,417. Prior to the exercise, the total number of shares in Camurus amounted to 54,233,773, corresponding to 54,233,773 votes. As of 29 January 2021, the total number of shares in Camurus amounts to 54,235,190, corresponding to 54,235,190 votes. For more informationFredrik Tiberg, President & CEOTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com Fredrik Joabsson,

Ericsson reports fourth quarter and full-year results 2020

Fourth quarter highlights · Sales adjusted for comparable units and currency grew by 13% YoY mainly driven by sales in North East Asia, Europe and North America. Reported sales were SEK 69.6 (66.4) b. · Gross margin excluding restructuring charges improved to 40.6% (37.1%) with margin improvements in all segments. Reported gross margin improved to 40.6% (36.8%). · Operating income excluding restructuring charges improved to SEK 11.0 b. (15.8% operating margin) from SEK 6.5 b. (9.7% operating margin) mainly driven by Networks. Reported operating income was SEK 11.0 (6.1) b. ·

Year-end report January–December 2020

Return to underlying sales growth  KEY HIGHLIGHTS · Sales volumes increased by 5%  · Continued positive development of the ramp-up at Gruvön (KM7)  · Cost and efficiency programme exceeding target  · Strong operating cash flow · The Board of Directors proposes dividend of SEK 4.30 per share  Quarterly data · Net sales amounted to SEK 5 803 million (5 815). Excluding currency effects sales grew by 2% · Adjusted EBITDA* was SEK 568 million (618). Lower sales prices and higher maintenance costs were partly offset by lower fibre costs and a positive trend of the

BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020

·Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer  Bergen, Norway, 29 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an update from its Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC) patients at an oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC).

Telia Company Year-end report January-December 2020

Strong cash flow generation  Fourth Quarter Summary · Net sales grew 2.7 percent to SEK 23,464 million (22,838) and like for like[4], net sales declined 1.9 percent. Service revenues grew 4.0 percent to SEK 19,765 million (19,007) and like for like[4], service revenues declined 2.1 percent. Adjusted EBITDA declined 5.5 percent to SEK 7,477 million (7,914) and like for like[4], adjusted EBITDA declined 6.6 percent. · COVID-19 had an estimated negative impact of SEK 400 million and SEK 200 million on service revenues and adjusted EBITDA, respectively. · Operating income

DNB Markets - Nexam Chemical: Significant Potential On The Horizon

Nexam Chemical continues to deliver on our forecasts and we are gaining confidence in its profitable growth journey. Growth remained impressive in Q4 at 46%, which we believe highlights the company’s significant potential beyond its 2022 sales target, driven by a good business case for the plastic industry to increase recyclability and better use of plastic materials. The stock is selling at a 2022e EV/sales of 2.6x. We have lifted our fair value to SEK13–17 (10–14).Details from the Q4 report. We find it encouraging that the company continues to deliver on our forecasts with Q4 sales 3%

Definitive strategic partnership agreements with Michelin delayed

All parts of the definitive agreements between Scandinavian Enviro Systems (publ) (“Enviro” or “The Company”) and Michelin concerning the announced strategic partnership have not yet been fully negotiated. Accordingly, Enviro will not be convening an Extraordinary General Meeting (EGM) for approval of the agreements in January as previously announced. Both Enviro and Michelin expect that the agreements will be fully negotiated in the near future. As previously communicated, the agreements must first be approved by Enviro’s owners at an EGM before they can enter into force. Notice of the EGM

Scandion Oncology adjusts the PANTAX pancreatic cancer study

Scandion Oncology A/S (“Scandion” or the “Company”) has submitted an amendment to the Danish Medicines Agency regarding the PANTAX study. The amendment is based on the learnings obtained from treating the first 12 patients in the CORIST study and will contribute to an optimization of the PANTAX clinical trials. The processing time for the amendment is expected to be approximately four weeks, which on top of the current impact of the COVID-19 pandemic could delay the planned readout from the study into Q4 2021.In Scandion’s PANTAX Ib study, patients with inoperable or metastatic pancreatic

Q-Free: Acceptances received under mandatory offer to acquire all shares in Q-Free ASA

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, any jurisdiction in which the making of the Offer, the distribution of this stock exchange announcement or the acceptance of any tender of shares would contravene applicable laws or regulations. (Oslo, 28 January 2021): Reference is made to the mandatory offer (the “Offer”) from Rieber & Søn AS (the “Offeror”) to acquire all shares in Q-Free ASA (“Q-Free” or the “Company”) pursuant to an offer document

BillerudKorsnäs invests in a new recovery boiler at Frövi

The Board of Directors of BillerudKorsnäs has decided to invest in a new recovery boiler at the Frövi mill. An investment that ensures long-term operation at the production site.To secure an environmentally improved, stable and efficient pulp and board production, BillerudKorsnäs will invest in a new recovery boiler at the Frövi mill. The total investment is estimated to SEK 2.6 billion and the new recovery boiler is planned to be in operation at the end of 2023.“The Frövi mill is a strategic asset for BillerudKorsnäs and the investment is a good platform for future development. A new

Tikkurila has received a binding proposal from Akzo Nobel to acquire all shares of Tikkurila, subject to the Board of Tikkurila recommending the offer and Oras Invest undertaking to accept the offer

Tikkurila has received a binding proposal from Akzo Nobel to acquire all shares of Tikkurila, subject to the Board of Tikkurila recommending the offer and Oras Invest undertaking to accept the offer TIKKURILA OYJTender OfferJanuary 28, 2021 at 7.25 p.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH A POTENTIAL TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. Tikkurila Oyj (“Tikkurila” or the “Company”) announced on

ITAB expects higher adjusted EBITDA result for the financial year 2020 compared to the preliminary guidance from 10 July 2020

ITAB Shop Concept AB (publ) (“ITAB”) expects to report an adjusted EBITDA result, before non-recurring costs for the financial year ending 31 December 2020, which will be significantly higher than communicated in ITAB's preliminary guidance on 10 July 2020.The improvement in results is explained by increased sales with higher profitability and earlier effects of the company's savings than previously anticipated. The uncertainty regarding distribution and production due to the ongoing pandemic has made it difficult to forecast with precision. Adjusted EBITDA for the financial year 2020

Nomination committee appointed for the 2021 Annual General Meeting of Scandinavian Biogas Fuels International AB

In accordance with a resolution from the Extraordinary General Meeting, the Nomination Committee for the Annual General Meeting of Scandinavian Biogas Fuels International AB shall consist of four members, representing the three largest shareholders as of the last day of December 2020, and the Chairman of the Board. If the shareholder does not exercise his right to appoint a member of the Nomination Committee, the next largest shareholder shall have the right to appoint a member of the Nomination Committee. Based on the above, the Nomination Committee prior to the 2021 Annual General

Outcome of impairment test for Lindex, Stockmann Group's updated guidance for 2020 and a change of the reporting method for the real estate properties

STOCKMANN plc, Inside Information 28.1.2021 at 18:30 EET The book value of Lindex’s intangible assets adjusted to EUR 368 million due to the COVID-19 pandemic The ongoing and re-escalated COVID-19 pandemic increases uncertainty in Lindex’s main markets and especially the short-term business environment is challenging.  Stockmann Group has concluded an impairment test for Lindex's goodwill.  As a result, Stockmann will recognise approximately EUR 250 million in impairment related to Lindex’s goodwill in its fourth-quarter consolidated income statement. The write-down will be

Invitation to AddLife Year-end report presentation on 3 February 2021

AddLife will release the year-end report on 3 February 2021 at 1.00 pm. A presentation in which Kristina Willgård, CEO and Martin Almgren, CFO comment on the report will be held on the same day at 3.00 pm and can be followed via teleconference or audio broadcast. AddLife welcomes investors, analysts and media. The report will be available at www.add.life/en/investors/financial-reports-and-presentations/The presentation will be held in English and is followed by a question and answer session. After the presentation, a recorded version will be available on the same page. To

Axactor SE - Registration of share capital increase following the private placement and issuance of consideration shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, Norway – 28 January 2021 AXACTOR ANNOUNCES REGISTRATION OF SHARE CAPITAL INCREASE Reference is made to (i) the stock exchange announcements by Axactor SE (OSE: ACR) ("Axactor”) on 9 December 2020 regarding a private placement of 40,000,000 new shares (the “

Heimstaden Establishes Medium Term Note Programme

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

There are no items matching the current filter
There are no more items matching the current filter
Back to top